Anti-CD52 targeting is a very promising therapy for B cell malignancies and autoimmune diseases including rheumatoid arthritis and multiple sclerosis; however, the current standard treatment, alemtuzumab, produces ADAs in a high frequency of patients [27][28]. Here, CD52 is linked to autoimmune disease.